Reported Standalone quarterly numbers for Sun Pharma Advanced Research Company are:
Net Sales at Rs 16.81 crore in June 2024 down 29.81% from Rs. 23.95 crore in June 2023.
Story continues below Advertisement
Quarterly Net Loss at Rs. 96.84 crore in June 2024 down 1.56% from Rs. 95.35 crore in June 2023.
EBITDA stands negative at Rs. 93.56 crore in June 2024 down 1.71% from Rs. 91.99 crore in June 2023.
Sun Pharma Adv shares closed at 217.02 on August 05, 2024 (NSE) and has given -40.35% returns over the last 6 months and -6.90% over the last 12 months.
Story continues below Advertisement
| Sun Pharma Advanced Research Company | | Standalone Quarterly Results | in Rs. Cr. |
|
| Jun'24 | Mar'24 | Jun'23 | | Net Sales/Income from operations | 16.81 | 16.56 | 23.95 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 16.81 | 16.56 | 23.95 | | EXPENDITURE | | Consumption of Raw Materials | 4.53 | 7.46 | 5.17 | | Purchase of Traded Goods | -- | -- | -- | | Increase/Decrease in Stocks | -- | -- | -- | | Power & Fuel | -- | -- | -- | | Employees Cost | 28.94 | 26.72 | 31.12 | | Depreciation | 2.76 | 2.69 | 3.10 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 78.46 | 89.90 | 89.84 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | -97.88 | -110.21 | -105.28 | | Other Income | 1.56 | 4.40 | 10.19 | | P/L Before Int., Excpt. Items & Tax | -96.32 | -105.81 | -95.09 | | Interest | 0.52 | 0.88 | 0.26 | | P/L Before Exceptional Items & Tax | -96.84 | -106.69 | -95.35 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | -96.84 | -106.69 | -95.35 | | Tax | -- | -- | -- | | P/L After Tax from Ordinary Activities | -96.84 | -106.69 | -95.35 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -96.84 | -106.69 | -95.35 | | Equity Share Capital | 32.45 | 32.45 | 32.45 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -2.98 | -3.29 | -2.94 | | Diluted EPS | -2.98 | -3.29 | -2.94 | | EPS After Extra Ordinary | | Basic EPS | -2.98 | -3.29 | -2.94 | | Diluted EPS | -2.98 | -3.29 | -2.94 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
